1221 related articles for article (PubMed ID: 33197225)
1. Systemic Therapy for Advanced Hepatocellular Carcinoma: ASCO Guideline.
Gordan JD; Kennedy EB; Abou-Alfa GK; Beg MS; Brower ST; Gade TP; Goff L; Gupta S; Guy J; Harris WP; Iyer R; Jaiyesimi I; Jhawer M; Karippot A; Kaseb AO; Kelley RK; Knox JJ; Kortmansky J; Leaf A; Remak WM; Shroff RT; Sohal DPS; Taddei TH; Venepalli NK; Wilson A; Zhu AX; Rose MG
J Clin Oncol; 2020 Dec; 38(36):4317-4345. PubMed ID: 33197225
[TBL] [Abstract][Full Text] [Related]
2. Systemic Therapy for Advanced Hepatocellular Carcinoma: ASCO Guideline Update.
Gordan JD; Kennedy EB; Abou-Alfa GK; Beal E; Finn RS; Gade TP; Goff L; Gupta S; Guy J; Hoang HT; Iyer R; Jaiyesimi I; Jhawer M; Karippot A; Kaseb AO; Kelley RK; Kortmansky J; Leaf A; Remak WM; Sohal DPS; Taddei TH; Wilson Woods A; Yarchoan M; Rose MG
J Clin Oncol; 2024 May; 42(15):1830-1850. PubMed ID: 38502889
[TBL] [Abstract][Full Text] [Related]
3. Outcomes of Patients with Child-Pugh B and Unresectable Hepatocellular Carcinoma Undergoing First-Line Systemic Treatment with Sorafenib, Lenvatinib, or Atezolizumab Plus Bevacizumab.
Kikugawa C; Uchikawa S; Kawaoka T; Kinami T; Yano S; Amioka K; Naruto K; Ando Y; Yamaoka K; Tsuge M; Kosaka Y; Ohya K; Mori N; Takaki S; Tsuji K; Kouno H; Kohno H; Morio K; Moriya T; Nonaka M; Aisaka Y; Masaki K; Honda Y; Naeshiro N; Hiramatsu A; Aikata H; Oka S
Oncology; 2024; 102(3):239-251. PubMed ID: 37729889
[TBL] [Abstract][Full Text] [Related]
4. Systemic Therapy and Sequencing Options in Advanced Hepatocellular Carcinoma: A Systematic Review and Network Meta-analysis.
Sonbol MB; Riaz IB; Naqvi SAA; Almquist DR; Mina S; Almasri J; Shah S; Almader-Douglas D; Uson Junior PLS; Mahipal A; Ma WW; Jin Z; Mody K; Starr J; Borad MJ; Ahn DH; Murad MH; Bekaii-Saab T
JAMA Oncol; 2020 Dec; 6(12):e204930. PubMed ID: 33090186
[TBL] [Abstract][Full Text] [Related]
5. A concise review of the changing landscape of hepatocellular carcinoma.
Draper A
Am J Manag Care; 2020 Oct; 26(10 Suppl):S211-S219. PubMed ID: 33052638
[TBL] [Abstract][Full Text] [Related]
6. Immune-Checkpoint Inhibitors for Advanced Hepatocellular Carcinoma: A Synopsis of Response Rates.
Shek D; Read SA; Nagrial A; Carlino MS; Gao B; George J; Ahlenstiel G
Oncologist; 2021 Jul; 26(7):e1216-e1225. PubMed ID: 33818870
[TBL] [Abstract][Full Text] [Related]
7. First-Line Targeted Therapy for Hepatocellular Carcinoma: Role of Atezolizumab/Bevacizumab Combination.
Tella SH; Kommalapati A; Mahipal A; Jin Z
Biomedicines; 2022 Jun; 10(6):. PubMed ID: 35740326
[TBL] [Abstract][Full Text] [Related]
8. Prognosis and treatment pattern of advanced hepatocellular carcinoma after failure of first-line atezolizumab and bevacizumab treatment.
Chen CT; Feng YH; Yen CJ; Chen SC; Lin YT; Lu LC; Hsu CH; Cheng AL; Shao YY
Hepatol Int; 2022 Oct; 16(5):1199-1207. PubMed ID: 35986846
[TBL] [Abstract][Full Text] [Related]
9. Systemic targeted and immunotherapy for advanced hepatocellular carcinoma.
Cersosimo RJ
Am J Health Syst Pharm; 2021 Jan; 78(3):187-202. PubMed ID: 33211092
[TBL] [Abstract][Full Text] [Related]
10. AGA Clinical Practice Guideline on Systemic Therapy for Hepatocellular Carcinoma.
Su GL; Altayar O; O'Shea R; Shah R; Estfan B; Wenzell C; Sultan S; Falck-Ytter Y
Gastroenterology; 2022 Mar; 162(3):920-934. PubMed ID: 35210014
[TBL] [Abstract][Full Text] [Related]
11. Optimizing Survival and the Changing Landscape of Targeted Therapy for Intermediate and Advanced Hepatocellular Carcinoma: A Systematic Review.
Lim H; Ramjeesingh R; Liu D; Tam VC; Knox JJ; Card PB; Meyers BM
J Natl Cancer Inst; 2021 Feb; 113(2):123-136. PubMed ID: 32898239
[TBL] [Abstract][Full Text] [Related]
12. Critical Appraisal of Guideline Recommendations on Systemic Therapies for Advanced Hepatocellular Carcinoma: A Review.
Cappuyns S; Corbett V; Yarchoan M; Finn RS; Llovet JM
JAMA Oncol; 2024 Mar; 10(3):395-404. PubMed ID: 37535375
[TBL] [Abstract][Full Text] [Related]
13. Navigating the new landscape of second-line treatment in advanced hepatocellular carcinoma.
Rimassa L; Wörns MA
Liver Int; 2020 Aug; 40(8):1800-1811. PubMed ID: 32432830
[TBL] [Abstract][Full Text] [Related]
14. Comparative Efficacy of Cabozantinib and Regorafenib for Advanced Hepatocellular Carcinoma.
Kelley RK; Mollon P; Blanc JF; Daniele B; Yau T; Cheng AL; Valcheva V; Marteau F; Guerra I; Abou-Alfa GK
Adv Ther; 2020 Jun; 37(6):2678-2695. PubMed ID: 32424805
[TBL] [Abstract][Full Text] [Related]
15. Role of immunotherapy in the management of hepatocellular carcinoma: current standards and future directions.
Weinmann A; Galle PR
Curr Oncol; 2020 Nov; 27(Suppl 3):S152-S164. PubMed ID: 33343209
[TBL] [Abstract][Full Text] [Related]
16. Selection of first-line systemic therapies for advanced hepatocellular carcinoma: A network meta-analysis of randomized controlled trials.
Han Y; Zhi WH; Xu F; Zhang CB; Huang XQ; Luo JF
World J Gastroenterol; 2021 May; 27(19):2415-2433. PubMed ID: 34040331
[TBL] [Abstract][Full Text] [Related]
17. Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial.
Zhu AX; Kang YK; Yen CJ; Finn RS; Galle PR; Llovet JM; Assenat E; Brandi G; Pracht M; Lim HY; Rau KM; Motomura K; Ohno I; Merle P; Daniele B; Shin DB; Gerken G; Borg C; Hiriart JB; Okusaka T; Morimoto M; Hsu Y; Abada PB; Kudo M;
Lancet Oncol; 2019 Feb; 20(2):282-296. PubMed ID: 30665869
[TBL] [Abstract][Full Text] [Related]
18. Atezolizumab/bevacizumab or lenvatinib in hepatocellular carcinoma: Multicenter real-world study with focus on bleeding and thromboembolic events.
Ben Khaled N; Möller M; Jochheim LS; Leyh C; Ehmer U; Böttcher K; Pinter M; Balcar L; Scheiner B; Weich A; Leicht HB; Zarka V; Ye L; Schneider J; Piseddu I; Öcal O; Rau M; Sinner F; Venerito M; Gairing SJ; Förster F; Mayerle J; De Toni EN; Geier A; Reiter FP
JHEP Rep; 2024 Jun; 6(6):101065. PubMed ID: 38798717
[TBL] [Abstract][Full Text] [Related]
19. Current treatment options for hepatocellular carcinoma.
Eugen K
Klin Onkol; 2020; 33(Supplementum 3):20-25. PubMed ID: 33213161
[TBL] [Abstract][Full Text] [Related]
20. Non-immunotherapy options for the first-line management of hepatocellular carcinoma: exploring the evolving role of sorafenib and lenvatinib in advanced disease.
Perera S; Kelly D; O'Kane GM
Curr Oncol; 2020 Nov; 27(Suppl 3):S165-S172. PubMed ID: 33343210
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]